New biomarker signals poor response in prostate cancer
from Medscape (free login required)
A new test can identify men with castration-resistant prostate cancer (CRPC) who are likely to have a poorer response to the targeted hormonal therapies abiraterone acetate (Zytiga, Janssen) and enzalutamide (Xtandi, Medivation/Astellas), say British researchers. Many prostate cancers rely on the androgen receptor gene (AR) to grow, the authors explain. The new test finds tumors with multiple copies of AR.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063